GSK股东批准与诺华的超200亿美元资产置换交易
路透社12月18日伦敦报道，GSK股东大会通过了一项与瑞士诺华资产置换的计划，两大制药公司将置换超过200亿美元的资产。
GSK在周四的会议上以绝对压倒性的方式通过了该项交易，交易预计将于2015年上半年完成。
交易内容包括：GSK收购诺华的疫苗业务，诺华收购GSK的抗癌药业务，两大集团在今年4月首次透露资产置换意向。
美国反垄断部门已经在11月份批准了GSK与诺华的资产置换交易，此前诺华刚同意剥离其Habitrol（一种戒烟帖）业务。预计欧洲反垄断监管机构于2015年1月14日决定是否同意该交易。
GSK shareholders approve asset swap deal with Novartis
LONDON, Dec 18 (Reuters) -Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets.
GSK said a meeting on Thursday had approved the transaction by an overwhelming majority and the deal was on track to complete in the first half of 2015.
The transaction, which includes GSK buying Novartis' vaccines business, Novartis purchasing GSK's cancer drugs, and the two groups tying up in consumer healthcare, was first unveiled in April.
U.S. antitrust regulators approved the deal in November, after Novartis agreed to divest its nicotine patch Habitrol, while European Union antitrust regulators will decide by Jan. 14 whether to clear the arrangement.
